<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>plug-and-play &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/plug-and-play/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 26 Oct 2026 21:37:32 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>plug-and-play &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Preclinical plug-and-play CAR T cells can be reconfigured after treatment</title>
		<link>https://bioengineer.org/preclinical-plug-and-play-car-t-cells-can-be-reconfigured-after-treatment/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 26 Oct 2026 21:37:32 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[acute myeloid leukemia]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[CAR-T cells]]></category>
		<category><![CDATA[City of Hope]]></category>
		<category><![CDATA[meCAR T cells]]></category>
		<category><![CDATA[plug-and-play]]></category>
		<category><![CDATA[preclinical research]]></category>
		<category><![CDATA[protein adaptors]]></category>
		<category><![CDATA[solid tumors]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[tumor heterogeneity]]></category>
		<category><![CDATA[unveils]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=456256</guid>

					<description><![CDATA[An animal study by City of Hope researchers shows that modular CAR T cells can accept engineered adaptors after treatment, offering a preclinical route to retargeting engineered immune cells as solid tumors evolve.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">456256</post-id>	</item>
	</channel>
</rss>
